Skip to main content
. Author manuscript; available in PMC: 2023 Oct 26.
Published in final edited form as: Hypertension. 2023 Jan 9;80(3):e46–e57. doi: 10.1161/HYP.0000000000000224

Figure 1.

Figure 1.

Putative mechanisms whereby major classes of anti-cancer therapies cause hypertension. VEGF, Vascular epidemanl growth factor; VEGFR, VEGF receptor; BTK, Brutons tyrosine kinase; PI3K, Phosphoinositide 3-kinases; CD47, Cluster of Differentiation 47; MEK, mitogen-actvated protein kinase kinase.